Till Milde

List of Publications by Year
in descending order

144	19,210	44069 48	30922 102
papers	citations	h-index	g-index

163	163	163	21849
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	5.2	12
2	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers, 2022, 14, 471.	3.7	9
3	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. Cancers, 2022, 14, 679.	3.7	4
4	Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models. Cancers, 2022, 14, 849.	3.7	13
5	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. Neuro-Oncology, 2022, 24, i42-i42.	1.2	0
6	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation. Neuro-Oncology, 2022, 24, i168-i169.	1.2	0
7	MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register. Neuro-Oncology, 2022, 24, i113-i114.	1.2	0
8	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
9	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. Neuro-Oncology, 2022, 24, i154-i154.	1.2	0
10	PATH-13. Methylation analysis in the diagnosis of pediatric CNS tumors; a single center experience. Neuro-Oncology, 2022, 24, i161-i161.	1.2	0
11	LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. Neuro-Oncology, 2022, 24, i91-i91.	1.2	0
12	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i91-i92.	1.2	0
13	LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. Neuro-Oncology, 2022, 24, i93-i93.	1.2	0
14	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	1.2	0
15	MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma. Neuro-Oncology, 2022, 24, i113-i113.	1.2	0
16	NFB-13. Rhabdoid Tumor Predisposition Syndrome (RTPS) â€“ Finding Evidence by systematic Analyses. Neuro-Oncology, 2022, 24, i130-i131.	1.2	0
17	LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro-Oncology, 2022, 24, i90-i90.	1.2	1
18	LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i94-i94.	1.2	0

#	Article	IF	Citations
19	DDEL-01. The role of key pharmacodynamic and pharmacokinetic parameters in drug response prediction of pediatric tumors in the precision oncology study INFORM. Neuro-Oncology, 2022, 24, i33-i34.	1.2	0
20	ATRT-05. Infants and newborns with atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors: a unique and challenging population. Neuro-Oncology, 2022, 24, i2-i3.	1.2	0
21	LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures. Neuro-Oncology, 2022, 24, i93-i94.	1.2	0
22	HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma. Neuro-Oncology, 2022, 24, i76-i76.	1.2	0
23	Multiomics analysis of pediatric solid tumors within the INFORM precision oncology study: From functional drug profiling to biomarker identification.. Journal of Clinical Oncology, 2022, 40, 10036-10036.	1.6	0
24	Accurate calling of KIAA1549â€BRAF fusions from DNA of human brain tumours using methylation arrayâ€based copy number and gene panel sequencing data. Neuropathology and Applied Neurobiology, 2021, 47, 406-414.	3.2	12
25	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro-Oncology, 2021, 23, 226-239.	1.2	22
26	Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Science Translational Medicine, 2021, 13, .	12.4	26
27	Predisposition to cancer in children and adolescents. The Lancet Child and Adolescent Health, 2021, 5, 142-154.	5.6	53
28	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
29	EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i5-i5.	1.2	0
30	EMBR-11. SYNERGISTIC DRUG COMBINATIONS FOR THE TREATMENT OF MYC AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i7-i8.	1.2	0
31	LGG-04. MULTIOMIC ANALYSIS OF MAPK PATHWAY ACTIVITY IN PEDIATRIC PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2021, 23, i31-i32.	1.2	0
32	Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. Neuro-Oncology, 2021, 23, 1634-1646.	1.2	19
33	EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM. Neuro-Oncology, 2021, 23, i47-i48.	1.2	0
34	LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2021, 23, i33-i34.	1.2	0
35	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	7.7	36
36	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110

#	Article	IF	Citations
37	Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers, 2021, 13, 4476.	3.7	8
38	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nature Communications, 2021, 12, 5530.	12.8	24
39	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica, 2021, 142, 1065-1069.	7.7	16
40	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
41	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
42	SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma. Cancers, 2021, 13, 6077.	3.7	16
43	Response to trametinib treatment in progressive pediatric low-grade glioma patients. Journal of Neuro-Oncology, 2020, 149, 499-510.	2.9	68
44	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. Cancer Research, 2020, 80, 5393-5407.	0.9	38
45	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell, 2020, 38, 44-59.e9.	16.8	94
46	Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts. Pharmaceuticals, 2020, 13, 345.	3.8	19
47	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. Journal of Personalized Medicine, 2020, 10, 290.	2.5	18
48	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
49	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer, 2020, 20, 523.	2.6	24
50	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	27.8	94
51	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells. Molecular Cancer Therapeutics, 2020, 19, 1736-1750.	4.1	13
52	LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2020, 22, iii368-iii368.	1.2	0
53	LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY. Neuro-Oncology, 2020, 22, iii369-iii369.	1.2	0
54	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. Neuro-Oncology, 2020, 22, iii311-iii311.	1.2	0

#	Article	IF	Citations
55	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. Neuro-Oncology, 2020, 22, iii311-iii312.	1.2	0
56	MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. Neuro-Oncology, 2020, 22, iii388-iii388.	1.2	0
57	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nature Reviews Cancer, 2019, 19, 420-438.	28.4	98
58	MEDU-01. HDACi AND PLK1i ACT SYNERGISTICALLY IN MYC-AMPLIFIED MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii103-ii103.	1.2	1
59	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathologica, 2019, 138, 827-835.	7.7	42
60	LGG-11. ESTABLISHMENT OF A HUMAN 3-DIMENSIONAL LOW-GRADE GLIOMA TUMOR MODEL IN INDUCED PLURIPOTENT STEM CELL DERIVED BRAIN ORGANOIDS. Neuro-Oncology, 2019, 21, ii101-ii101.	1.2	0
61	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications, 2019, 10, 2400.	12.8	37
62	GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. Neuro-Oncology, 2019, 21, ii83-ii83.	1.2	1
63	Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2â€‰years of age â€“ a multicenter retrospective study. Orphanet Journal of Rare Diseases, 2019, 14, 96.	2.7	90
64	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. European Journal of Cancer, 2019, 114, 27-35.	2.8	51
65	Retinoblastoma with late metastatic spreadâ€”a case report. Pediatric Blood and Cancer, 2019, 66, e27656.	1.5	1
66	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	1.2	0
67	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clinical Epigenetics, 2019, 11, 188.	4.1	27
68	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
69	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	7.0	55
70	INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.. Journal of Clinical Oncology, 2019, 37, TPS10065-TPS10065.	1.6	5
71	Establishment of a 3-dimensional Low-grade Glioma Model in Induced Pluripotent Stem-cell-derived Brain Organoids. , 2019, 50, .		0
72	Characterization of a novel <scp>OTX</scp>2â€driven stem cell program in Group 3 and Group 4 medulloblastoma. Molecular Oncology, 2018, 12, 495-513.	4.6	16

#	Article	IF	Citations
73	Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors. Cell Cycle, 2018, 17, 811-822.	2.6	60
74	Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. Pediatric Blood and Cancer, 2018, 65, e26893.	1.5	21
75	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	27.8	170
76	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
77	LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2018, 20, i106-i106.	1.2	0
78	MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i130-i130.	1.2	0
79	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	7.7	118
80	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathologica, 2018, 136, 181-210.	7.7	308
81	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making â€" A Selected Case Series. Klinische Padiatrie, 2018, 230, 305-313.	0.6	8
82	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
83	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	7.7	104
84	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. Leukemia, 2017, 31, 2048-2056.	7.2	47
85	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro-Oncology, 2017, 19, 1607-1617.	1.2	39
86	Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance. Cell Death and Disease, 2017, 8, e3013-e3013.	6.3	43
87	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787
88	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget, 2017, 8, 11460-11479.	1.8	43
89	Abstract 1935: Molecular characterization of orthotopic patient-derived xenograft models of pediatric brain tumors. , 2017, , .		0
90	Abstract 509: Genomic profiling of acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link betweenATMmutations and chromothripsis. , 2017, , .		0

#	Article	IF	Citations
91	LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING. Neuro-Oncology, 2016, 18, iii84.3-iii84.	1.2	0
92	MB-57INTERACTION OF HDAC2 AND MYC IN GROUP 3 MEDULLOBLASTOMA - A NOVEL THERAPEUTIC TARGET. Neuro-Oncology, 2016, 18, iii110.1-iii110.	1.2	0
93	PCM-16MOLECULAR CHARACTERIZATION OF ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS. Neuro-Oncology, 2016, 18, iii142.3-iii142.	1.2	0
94	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	4.1	14
95	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
96	Next-generation personalised medicine for high-risk paediatric cancer patients â€“ The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	2.8	262
97	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	7.7	203
98	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
99	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
100	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Oncotarget, 2016, 7, 61860-61873.	1.8	27
101	Ependymoma. Molecular Pathology Library, 2015, , 67-75.	0.1	0
102	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	7.7	277
103	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathologica Communications, 2015, 3, 22.	5.2	66
104	Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 964, 212-221.	2.3	14
105	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 2014, 506, 445-450.	27.8	521
106	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	16.8	627
107	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature, 2014, 510, 537-541.	27.8	378
108	GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. Cancer Research, 2014, 74, 2604-2616.	0.9	54

#	Article	IF	Citations
109	Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups. , 2014, , .		0
110	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	21.4	674
111	Emerging Insights into the Ependymoma Epigenome. Brain Pathology, 2013, 23, 206-209.	4.1	21
112	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	16.8	633
113	Histone deacetylase 10 promotes autophagy-mediated cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2592-601.	7.1	168
114	MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Research, 2013, 41, 6018-6033.	14.5	87
115	Targeting of histone deacetylases in brain tumors. CNS Oncology, 2013, 2, 359-376.	3.0	22
116	Retinal angiogenesis suppression through small molecule activation of p53. Journal of Clinical Investigation, 2013, 123, 4170-4181.	8.2	24
117	Molecular approaches to ependymoma. Current Opinion in Neurology, 2012, 25, 745-750.	3.6	22
118	HD-MB03 is a novel GroupÂ3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. Journal of Neuro-Oncology, 2012, 110, 335-348.	2.9	110
119	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	16.8	1,551
120	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. Brain Pathology, 2012, 22, 848-860.	4.1	40
121	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
122	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	27.8	765
123	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathologica, 2012, 123, 529-538.	7.7	60
124	Abstract 3687: An integrative genomics approach identifies distinct molecular and epigenetic subgroups of pediatric glioblastoma. Cancer Research, 2012, 72, 3687-3687.	0.9	15
125	Progressively Metastasizing Ependymoma: Genomic Aberrations. , 2012, , 297-306.		0
126	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. Cancer Cell, 2011, 20, 143-157.	16.8	494

#	Article	IF	Citations
127	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathologica, 2011, 122, 637-650.	7.7	77
128	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e348-e349.	1.6	2
129	An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. Journal of Clinical Investigation, 2011, 121, 1344-1348.	8.2	68
130	Abstract 3453: Induction of differentiation in high-risk ependymoma stem-like cells by treatment with the HDAC inhibitor Vorinostat. , 2011, , .		0
131	Abstract 3458: Activated BRAF induces pilocytic astrocytomas in mice. , 2011, , .		0
132	Molecular Staging of Intracranial Ependymoma in Children and Adults. Journal of Clinical Oncology, 2010, 28, 3182-3190.	1.6	210
133	TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. Journal of Clinical Oncology, 2010, 28, 5188-5196.	1.6	100
134	Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsiveâ€“like behaviors in mice. Nature Medicine, 2010, 16, 598-602.	30.7	281
135	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. Clinical Cancer Research, 2010, 16, 3240-3252.	7.0	175
136	Abstract 31: Subgroup-specific molecular alterations may explain the tremendous clinical heterogeneity of intracranial ependymoma. , 2010, , .		0
137	Angiomodulin Is a Specific Marker of Vasculature and Regulates Vascular Endothelial Growth Factor-Aâ€“Dependent Neoangiogenesis. Circulation Research, 2009, 105, 201-208.	4.5	47
138	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. Genes Chromosomes and Cancer, 2009, 48, 229-238.	2.8	24
139	HDAC family: What are the cancer relevant targets?. Cancer Letters, 2009, 277, 8-21.	7.2	893
140	Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opinion on Investigational Drugs, 2009, 18, 1605-1617.	4.1	64
141	HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anti-Cancer Drugs, 2008, 19, 849-857.	1.4	24
142	CD133 expression is not restricted to stem cells, and both CD133+ and CD133â€“ metastatic colon cancer cells initiate tumors. Journal of Clinical Investigation, 2008, 118, 2111-20.	8.2	736
143	Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. Journal of Clinical Investigation, 2006, 116, 3277-3291.	8.2	95
144	Multifocal Osteochondroma After Repeated Irradiation in a Boy With Hodgkin Disease. Journal of Pediatric Hematology/Oncology, 2005, 27, 344-345.	0.6	5